NCT01709500
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
See it on ClinicalTrials.gov ↗249 people
47.4%
52.6%
118 womenmiddle line = equal numbers131 men
- Phase
- PHASE3
- Paid for by
- Regeneron Pharmaceuticals
- Finished
- 2015-01
- Health conditions
- Heterozygous Familial Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 53.2 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“…ude, but are not limited to: adverse effects on higher doses, advanced age, low body mass index, regional practices, local prescribing information, concomitant medications, co-morbid conditions such as impaired glucose tolerance/impaired fa…”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“LDL-C \<70 mg/dL (\<1.81 mmol/L) at the screening visit (week-2) in patients with history of documented cardiovascular disease”
Study titles and rules are shown in their original English.